Home » Sales of quadrivalent influenza vaccines decline, Jindike’s net profit attributable to its parent in 2021 will drop by 46.91% year-on-year jqknews

Sales of quadrivalent influenza vaccines decline, Jindike’s net profit attributable to its parent in 2021 will drop by 46.91% year-on-year jqknews

by admin
Sales of quadrivalent influenza vaccines decline, Jindike’s net profit attributable to its parent in 2021 will drop by 46.91% year-on-year jqknews


  JindickPublished on the evening of February 25thperformanceExpress, the company will achieve a total operating income of 396 million yuan in 2021, a year-on-year decrease of 32.85%;net profit82.2863 million yuan, a year-on-year decrease of 46.91%; the net profit attributable to the owner of the parent company after deducting non-recurring gains and losses was 66.2234 million yuan, a year-on-year decrease of 59.09%.

In response to the sharp decline in performance in 2021,JindickIt said that due to the impact of the new crown pneumonia epidemic and the nationwide implementation of the new crown vaccine booster and the vaccination of children under the age of 12, the company’s quadrivalent influenza vaccination has been greatly affected, resulting in a decline in product sales in 2021.At the same time, according to the market vaccination situation, the company changed the estimated sales return rate of the quadrivalent influenza vaccine from 0% to 10%, which was treated as a change in accounting estimates.Operating incomeA decrease of 194 million yuan, a year-on-year decrease of 32.85%.

The increase in the provision for impairment of assets (provision for inventory depreciation) also increasesJindickOne of the main reasons for the decline in performance in 2021. Jindike said that the company’s quadrivalent influenza vaccine has obvious seasonal characteristics, and the product is valid for 12 months. Due to the impact of the new crown pneumonia epidemic and new crown vaccination, the company has accrued and reduced the price of the inventory of the quadrivalent influenza vaccine that is not expected to be sold. Prepare 58.1458 million yuan.

See also  Reply: Standard Ethics assegna rating “E”

(Article source: ChinasecuritiesReport · China Securities Network)


Article source: China Securities Journal China Securities Network

Responsible editor: 91

Original title: Sales of quadrivalent influenza vaccines decline, Jindike’s net profit attributable to its parent in 2021 will drop by 46.91% year-on-year

Solemnly declare: Oriental Fortune.com releases this information for the purpose of disseminating more information and has nothing to do with the position of this site.

report

Share to WeChat Moments

Open WeChat,

Click “Discover” at the bottom

Use “Sweep”

You can share the webpage to the circle of friends

Scan the QR code to follow

Oriental Fortune official website WeChat

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy